Hamburg, Germany, 25 August 2022:
Evotec announces that the Company has been selected as a winner of the 2022 R&D 100 Award in the following category: Software and Services for their multi-omics analysis platform EVOpanHunter.

The R&D 100 Awards, now in its 60th year, is widely recognized to identify and celebrate the top 100 technology products, software and services of the year for their technological significance. This year, the Awards received entries from a dozen different countries/regions and nominations were judged by 50 respected industry professionals across the globe.

For further information, please follow this link to the R&D Award Winners 2022 website.

FORWARD-LOOKING STATEMENTS 

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.